Recombinant Human BCL2 Protein，His

BCL2 (B-cell lymphoma 2) is a crucial protein that plays a significant role in the regulation of apoptosis, or programmed cell death, which is essential for maintaining cellular homeostasis and preventing cancer development. Originally discovered in the context of B-cell lymphomas, the BCL2 gene is known to inhibit apoptosis, allowing for the survival of malignant cells and contributing to tumorigenesis. Given its pivotal role in cancer biology, BCL2 has become a prominent target for therapeutic intervention. Researchers have developed various BCL2 inhibitors to enhance the efficacy of existing cancer treatments and to overcome resistance to conventional therapies. The production of recombinant BCL2 protein has facilitated the study of its structure, function, and interactions with other apoptotic factors, thus advancing our understanding of its mechanisms in cellular survival and death. By using techniques such as molecular cloning and protein expression systems, scientists are able to produce BCL2 in sufficient quantities for biochemical assays and structural analyses. This research not only sheds light on the intricate balance between life and death in cells but also opens avenues for developing targeted therapies that could improve patient outcomes in cancers closely associated with BCL2 dysregulation. As the field progresses, the understanding of BCL2 and its related pathways continues to evolve, highlighting its importance in both basic research and clinical applications.